Home › Research › Cognitive tests and assessment
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.. Journal of clinical pharmacy and therapeutics, 2003-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. Acetylcholine esterase inhibitors are the only agents approved by the Food and Drug Administration for the treatment of Alzheimer's disease. All other agents prescribed for the treatment of Alzheimer's disease are used on an off-label basis.
What this study adds
Evidence grade: Low
This is a trial of 42 participants. This double-blind, randomized, placebo-controlled trial tested Salvia officinalis extract in patients with mild to moderate Alzheimer's disease. It evaluates a possible herbal treatment, not a proven cure or prevention for the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Akhondzadeh, S., Noroozian, M., Mohammadi, M., Ohadinia, S., Jamshidi, A. H., & Khani, M. (2003). Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of clinical pharmacy and therapeutics. https://doi.org/10.1046/j.1365-2710.2003.00463.x
Vancouver
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of clinical pharmacy and therapeutics. 2003. doi:10.1046/j.1365-2710.2003.00463.x. PMID: 12605619.
BibTeX
@article{akhondzadeh2003-12605619,
author = {Akhondzadeh, S. and Noroozian, M. and Mohammadi, M. and Ohadinia, S. and Jamshidi, A. H. and Khani, M.},
title = {{Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial}},
journal = {Journal of clinical pharmacy and therapeutics},
year = {2003},
doi = {10.1046/j.1365-2710.2003.00463.x},
pmid = {12605619},
url = {https://doi.org/10.1046/j.1365-2710.2003.00463.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Acetylcholine esterase inhibitors are the only agents approved by the Food and Drug Administration for the treatment of Alzheimer's disease.
- All other agents prescribed for the treatment of Alzheimer's disease are used on an off-label basis.
- Current research into new drugs is focused on agents that will prevent, slow down and/or halt the progress of the disease process.
- Salvia officinalis has been used in herbal medicine for many centuries.
Why it matters
This double-blind, randomized, placebo-controlled trial tested Salvia officinalis extract in patients with mild to moderate Alzheimer's disease. It evaluates a possible herbal treatment, not a proven cure or prevention for the disease.
Study details
- Participants42
- Evidence strengthLow
How this study scored 61/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 59 of the 96 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of clinical pharmacy and therapeutics) |
| Journal's citation record | 1 / 4 | Journal of Clinical Pharmacy and Therapeutics: journal h-index 100 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 1 / 4 | 42 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 344 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.8 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 4 / 6 | Cited 18.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 42 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author M Khani holds only 8 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Tehran University of Medical Sciences: institution h-index 810 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12605619) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 59 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 96 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.